Search research articles
Contact Us
Filters
Showing results (511-520 of 629) with videos related to
Page
of 63
Sort By:
Trials
|
June 27, 2022
Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses
Pepa Bruce, Kate Ainscough, Lee Hatter, et al.
Australian and New Zealand Journal of Public Health
|
January 17, 2026
Indigenous Measures for Protecting and Addressing Critical Trauma (IMPACT) - Project protocol
Courtney Ryder, Patrick Sharpe, Georga Sallows, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 26, 2022
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype
Klaus F Rabe, J Mark FitzGerald, Eric D Bateman, et al.
Injury
|
March 19, 2025
Lessons learned: The thematic analysis of eight countries with mature trauma systems
Amelia Levi, Shailvi Gupta, Sunder Balasubramaniam, et al.
Biomarker Insights
|
September 30, 2017
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation
Philip E Silkoff, Dave Singh, J Mark FitzGerald, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 19, 2008
Overdiagnosis of asthma in obese and nonobese adults
Shawn D Aaron, Katherine L Vandemheen, Louis-Philippe Boulet, et al.
BMC Pulmonary Medicine
|
February 8, 2006
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]
Don D Sin, S F Paul Man, Darcy D Marciniuk, et al.
Drug Safety
|
February 6, 2021
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
J Mark FitzGerald, Paul M O'Byrne, Eric D Bateman, et al.
The Lancet. Respiratory Medicine
|
June 28, 2021
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
William W Busse, Sally E Wenzel, Thomas B Casale, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
December 19, 2022
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
Ian D Pavord, Yamo Deniz, Jonathan Corren, et al.
Page
of 63
Search research articles
Search
Showing results (511-520 of 629) with videos related to
Sort By:
Page
of 63
Trials
|
June 27, 2022
Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses
Pepa Bruce, Kate Ainscough, Lee Hatter, et al.
Australian and New Zealand Journal of Public Health
|
January 17, 2026
Indigenous Measures for Protecting and Addressing Critical Trauma (IMPACT) - Project protocol
Courtney Ryder, Patrick Sharpe, Georga Sallows, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 26, 2022
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype
Klaus F Rabe, J Mark FitzGerald, Eric D Bateman, et al.
Injury
|
March 19, 2025
Lessons learned: The thematic analysis of eight countries with mature trauma systems
Amelia Levi, Shailvi Gupta, Sunder Balasubramaniam, et al.
Biomarker Insights
|
September 30, 2017
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation
Philip E Silkoff, Dave Singh, J Mark FitzGerald, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 19, 2008
Overdiagnosis of asthma in obese and nonobese adults
Shawn D Aaron, Katherine L Vandemheen, Louis-Philippe Boulet, et al.
BMC Pulmonary Medicine
|
February 8, 2006
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]
Don D Sin, S F Paul Man, Darcy D Marciniuk, et al.
Drug Safety
|
February 6, 2021
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
J Mark FitzGerald, Paul M O'Byrne, Eric D Bateman, et al.
The Lancet. Respiratory Medicine
|
June 28, 2021
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
William W Busse, Sally E Wenzel, Thomas B Casale, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
December 19, 2022
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
Ian D Pavord, Yamo Deniz, Jonathan Corren, et al.
Page
of 63